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Abstract 10 
Aims 11 
The beneficial effects of 4'-O-methylated flavonoids on induction of melanogenesis are well established. Here, we 12 
report the effect of isosakuranetin (Iso) on melanogenesis in B16BL6 melanoma cells and an analysis of the 13 
signaling pathways involved in this activity. 14 
Methods 15 
B16BL6 melanoma cells were treated with several concentration of Iso and melanin content was measured. 16 
Activation and expression of factors involved in melanogenesis were assessed via western blotting. 17 
Key findings 18 
Iso (15 and 30 µmol/L) strongly stimulated melanogenesis in a dose-dependent manner. Iso increased tyrosinase 19 
activity and up-regulated tyrosinase (Tyr), tyrosinase related protein 1 (TRP1), and tyrosinase related protein 2 20 
(TRP2) in a time-dependent manner. Iso decreased B16 cell proliferation at a concentration above 45 µmol/L, and 21 
had no effect on cell viability as revealed by MTT and trypan blue assays. Iso up-regulated expression of 22 
microphthalmia transcription factor (MITF), with a maximum effect after 12 h. H89, a specific inhibitor of PKA, 23 
showed that MITF up-regulation is mediated through PKA/CREB activation. Furthermore, Iso decreased 24 
phosphorylation of MITF at Ser73 after 24 h and 48 h of exposure, activating MITF and leading to up-regulation of 25 
Tyr, TRP1, and TRP2. Iso inhibited phosphorylation and activation of ERK1/2 after 12 h, while no significant 26 
effects on p38 and JNK phosphorylation were observed. Iso inhibited AKT phosphorylation and led to activation of 27 
GSK3β. 28 
Significance 29 
Iso stimulates melanogenesis in B16 melanoma cells via up-regulation of MITF. Furthermore, Iso-induced inhibition 30 
of ERK1/2 and PI3K/AKT signaling pathways activate MITF and subsequent expression of Tyr, TRP1, and TRP2. 31 
 32 
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Introduction 34 
Flavonoids, including isosakuranetin (Iso), are consumed daily in the diet as constituents of a variety of plant 35 
components. In addition, flavonoids are available in a wide range of natural products. Some flavonoids have been 36 
developed into therapeutic products due to their pharmacological activities. Previous investigations identified Iso as 37 
an important component of propolis, Baccharis dracunculifolia, Terminalia fagifolia, and Citrus sinensis [1-4]. Iso 38 
possesses a wide range of biochemical and pharmacological properties (Fig. 1), including antioxidative, 39 
neuroprotective, anticarcinogenic, and antiallergic properties [5, 6, 2]. 40 
Melanogenesis is the biosynthetic pathway for melanin production, which operates in dendritic melanocytes located 41 
in the lowest layer of the epidermis, as well as in hair and the eyes [7]. Melanin synthesis is mediated by at least 3 42 
important enzymes: tyrosinase (Tyr), tyrosinase-related protein 1 (TRP1), and tyrosinase-related protein 2 (TRP2) 43 
[8]. Tyr is the key enzyme involved in melanin synthesis and catalyzes hydroxylation of tyrosine to 44 
3,4-dihydroxyphenylalanine (DOPA), oxidation of DOPA to produce dopaquinone, and oxidation of 45 
5,6-dihydroxyindole (DHI) to indole-quinone [9]. TRP2 acts as a dopachrome tautomerase and functions together 46 
with TRP1 in melanin biosynthesis downstream of tyrosinase [10]. Two types of melanin are produced in mammals: 47 
red/yellow pheomelanin and black/brown eumelanin. Whereas tyrosinase is a common enzyme required for both 48 
eumelanin and pheomelanin synthesis, TRP1 and TRP2 seem to be primarily involved in eumelanin production [11, 49 
12]. 50 
When the melanocortin-1 receptor (MC1R) is stimulated upon release of alpha-melanocyte-stimulating hormone 51 
(α-MSH) and adrenocorticotropic hormone (ACTH) by keratinocytes after UV irradiation, the G-protein coupled to 52 
MC1R activates adenylate cyclase (AC), which in turn leads to cyclic AMP (cAMP) production. Activation of 53 
protein kinase A (PKA) by cAMP results in binding of CRE-binding protein (CREB) to the cAMP regulatory 54 
element (CRE) promoter, leading to transcription of the gene encoding microphthalmia transcription factor (MITF). 55 
Increased expression of MITF leads to elevated expression of genes in the melanogenic enzyme family, Tyr, TRP1, 56 
and TRP2, which stimulate melanin synthesis [13]. Activation of Ras by cAMP leads to activation of ERK1/2 57 
through MEK. Activated ERK1/2 phosphorylates MITF at Ser73, which is followed by MITF ubiquitination and 58 
degradation. Furthermore, p38 has been shown to be involved in UVR-induced melanogenesis via activation of 59 
MITF and subsequent up-regulation of Tyr expression [14].  60 
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In addition to transcriptional regulation, MITF can be regulated by posttranslational modification. Inhibition of PI3K 61 
and AKT by cAMP induces activation of GSK3β, which phosphorylates MITF at Ser289 and increases its binding to 62 
the M-box of the Tyr promoter, leading to expression of melanogenesis-related enzymes [15, 16].   63 
This study was conducted to understand the signaling pathways underlying Iso-induced melanogenesis in B16BL6 64 
melanoma cells. First, we determined whether Iso enhanced melanogenesis via up-regulation of Tyr, TRP1, and 65 
TRP2. Next, we assessed the effects of Iso on MITF expression and phosphorylation. Finally, we determined 66 
whether changes in MITF activation induced by Iso were mediated via inhibition of ERK1/2 and PI3K/AKT 67 
signaling pathways. 68 
 69 
Materials and methods 70 
Materials. The B16BL6 murine melanoma cell line was provided by RIKEN (Institute of Physical and Chemical 71 
Research Cell Bank, Tsukuba, Ibaraki, Japan). Iso was purchased from Extrasynthese Company (Genay, France). 72 
H89, and U0126 were obtained from Cayman Chemical Company (Michigan, USA). RPMI1640, L-DOPA, α-MSH, 73 
and anti-pMITF ser73 were purchased from Sigma-Aldrich (St. Louis, MO, USA). LY294002 and anti-MITF, 74 
anti-ERK1/2, anti-p-ERK1/2, anti-JNK, anti-p-JNK, anti-p38, anti-p-p38, anti-AKT, anti-p-AKT (Ser473), 75 
anti-p-AKT (Thr308), anti-p-GSK3β (Ser9), and anti-β-actin antibodies were obtained from Cell Signaling 76 
Technology (Tokyo, Japan). Anti-Tyr, anti-TRP1, and anti-TRP2 antibodies were purchased from Santa Cruz 77 
Biotechnology (Santa Cruz, CA, USA). 78 
 79 
Cell culture. B16 melanoma cells were cultured in RPMI1640 medium containing 10% FBS at 37 °C and 5% CO2. 80 
The cells were plated at a density of 3 × 105 cells/dish in 100-mm culture dishes and at a density of 4.5 × 104 81 
cells/well in 6-well plates. The cells were cultured and allowed to attach for 24 h, followed by treatment with Iso at 82 
the indicated concentrations and for the indicated periods of time. 83 
 84 
MTT assay. B16 melanoma cells were cultured in 24-well plates at a density of 1 × 104 cells/well. After 24 h, the 85 
cells were incubated for 72 hours in the presence of Iso at the indicated concentrations. The culture medium was 86 
removed and replaced with 500 µL of fresh culture medium containing 10% sterile filtered MTT (Sigma-Aldrich). 87 
After 3 hours, the formazan crystals were dissolved in 500 µL/well isopropanol and absorbance was measured at 88 
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570 nm against 630 nm. Inhibition of proliferation (%) was expressed as the percentage of viable treated cells in 89 
comparison with control cells. 90 
 91 
Trypan blue assay. B16 melanoma cells were seeded in 6-well plates at a density of 4.5 × 104 cells/well. After 24 h, 92 
the cells were incubated for a further 72 h in the presence of Iso at the indicated concentrations and cell viability was 93 
quantified by the trypan blue assay. After washing the cells twice with PBS, they were trypsinized, immediately 94 
stained with 0.5% trypan blue dye (Trypan Blue, Sigma-Aldrich) for 3 min, and observed under an optical 95 
microscope. Cell viability was calculated as the percentage (%) of unstained cells relative to the total number of 96 
counted cells. 97 
 98 
Measurement of melanin content. Melanin content was measured as described previously with some modifications 99 
[17]. B16 cells were seeded in 6-well plates at a density of 4.5 × 104 cells/well. After a 24-h incubation, the medium 100 
was replaced with a fresh medium containing Iso at 15 and 30 µmol/L and the cells were incubated for a further 72 h. 101 
The cells were washed twice in phosphate-buffered saline (PBS) and detached with 0.25% trypsin-EDTA solution, 102 
after which the solution containing the cells was transferred to a 1.5-mL tube. After centrifugation for 10 min at 103 
14000 rpm, the pellets were dissolved in 1N NaOH (100 µL) for 60 min at 80 °C. The absorbance of the sample at 104 
405 nm was measured with a microplate reader. 105 
 106 
Western blot analysis. B16 melanoma cells were cultured in 100-mm culture dishes at a density of 3 × 105 107 
cells/dish. After treatment, cells were harvested in RIPA buffer (50 mmol/L Tris-HCl (pH 7.4), 150 mmol/L NaCl, 108 
0.1% SDS, 0.5% Na-deoxycholate, 1% NP40, 1 mmol/L EDTA, 2 mmol/L NaF, and 1 mmol/L Na3VO4). Cells 109 
lysates were separated with SDS-PAGE and blotted on a PVDF membrane. After blocking in 2% BSA, the 110 
membrane was incubated with one of the selected primary antibodies (described in materials section) in TBS-T 111 
buffer overnight at 4 °C. Next, the membrane was incubated with the appropriate secondary antibodies for 1 h at RT 112 
and treated with the LuminoGLO reagent (Cell Signaling Technology). Protein bands were visualized using 113 
chemiluminescence (EZ-Capture MG, ATTO, Tokyo, Japan). The band intensity was analyzed using ImageJ 114 
analysis software (National Institutes of Health, Bethesda, MD, USA). 115 
 116 
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Intracellular tyrosinase activity assay. An intracellular tyrosinase activity assay was performed as previously 117 
described [18]. After 72 h, the cultured cells were washed with PBS and scraped in phosphate buffer (100 mmol/L, 118 
pH 6.8) supplemented with 1% Triton X100 and a protease inhibitor. The cell lysate was obtained after 119 
centrifugation at 14000 rpm for 10 min. The protein concentration was determined using a BCA protein assay kit 120 
and the concentrations of the samples were equilibrated. The cell lysate supernatants (containing 50 µg of protein) 121 
were transferred to 96-well plates and mixed with 100 µL of L-DOPA (0.2% in phosphate buffer). After incubation 122 
at 37 ºC for 1 h, the absorbance of each sample was measured at 475 nm using a microplate reader. Cellular 123 
tyrosinase activity was determined as the ratio of tyrosinase content to total protein content. 124 
 125 
Statistical analysis. Results are expressed as mean ± S.D. Comparisons between groups were analyzed with 126 
Student’s t-test. Differences were considered significant at a P-value ˂ 0.05. 127 
 128 
Results 129 
Iso activates melanin synthesis in B16 melanoma cells 130 
B16 melanocytes were cultured for 48 h and 72 h in the presence of the indicated concentrations of Iso. As shown in 131 
Fig. 2A, Iso stimulated melanin accumulation in a dose-dependent manner. In addition, Iso at 30 µmol/L gradually 132 
increased the expression of Tyr, TRP1, and TRP2 after 48 and 72 h (Fig. 2B). 133 
 134 
Iso decreases the proliferation rate of B16 melanoma cells without affecting viability 135 
To investigate whether Iso is cytotoxic to B16 melanocytes, cells were cultured for 72 h in the presence of several 136 
concentrations of Iso (0–75 µmol/L). The MTT assay showed that Iso decreased the number of cells at 137 
concentrations greater than 45 µmol/L (Fig. 3A). Further analysis of trypan blue staining demonstrated that Iso did 138 
not affect the viability of B16 melanocytes, but showed that Iso decreased their proliferation rate (Fig. 3B). 139 
 140 
Iso increases tyrosinase activity in a dose-dependent manner 141 
Cellular B16 tyrosinase activity was assayed using L-DOPA as a substrate. After Iso treatment, cells were lysed and 142 
tyrosinase activity was assessed. The tyrosinase activity of B16 melanocytes treated with 15 and 30 µmol/L Iso for 143 
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72 h was significantly increased by 2- and 3.2-fold, respectively, in comparison with that of the control cells (Fig. 4). 144 
Treatment with positive control MSH increased tyrosinase activity by 1.6-fold. 145 
 146 
Iso up-regulated MITF expression through PKA/CREB pathway activation, and decreased MITF 147 
phosphorylation in B16 melanoma cells  148 
To investigate the effect of Iso on melanogenesis-related protein expression and phosphorylation, B16 melanocytes 149 
were treated with 30 µmol/L Iso for 0, 3, 6, 12, 24, and 48 h. As shown in Fig. 5A, MITF expression increased 150 
rapidly after Iso treatment and reached a maximum level after 12 h. MITF expression was slightly decreased after 24 151 
and 48 h of Iso treatment, but protein expression remained elevated in comparison with that measured at 0 h. 152 
Similarly, phosphorylation of MITF at Ser73 was increased after 3, 6 and 12 h of Iso exposure, decreased after 24 h, 153 
and almost completely abolished at 48 h (Fig. 5A). To examine whether Iso increased MITF expression via 154 
PKA/CREB activation, a PKA specific inhibitor H89 was used. Preincubation of B16 melanocytes for 1 h with H89 155 
(5 µmol/L) and then the addition of Iso (30 µmol/L) for further 72 h in the continued presence of the inhibitor 156 
significantly reduced the Iso-induced melanogenesis (Fig. 5B). These findings indicate that Iso stimulates 157 
melanogenesis through PKA/CREB activation and subsequent MITF up-regulation. 158 
 159 
Effects of Iso on MAP kinases in B16 melanoma cells 160 
To elucidate the mechanisms underlying Iso-induced melanogenesis, we examined the influence of Iso on ERK, p38, 161 
and JNK expression and phosphorylation after 0, 3, 6, 12, 24, and 48 h. Although Iso did not affect the expression of 162 
ERK, p38, or JNK, Iso markedly decreased phosphorylation of ERK after 3 h of exposure in a time-dependent 163 
manner. Iso did not affect phosphorylation of p38 or JNK (Fig. 6A). Exposure to 10 µmol/L U0126, a selective ERK 164 
inhibitor, increased melanin accumulation in B16 melanocytes by 3.5 times in comparison with that of the control 165 
group, demonstrating the capability of ERK to modulate melanin accumulation (Fig. 6B).  166 
 167 
Effect of Iso on AKT phosphorylation in B16 melanoma cells. 168 
Several previous studies have described the relationship between PI3K/AKT signaling and melanogenesis in 169 
melanocytes. Therefore, we determined the effect of Iso on AKT activation after 0, 3, 6, 12, 24, and 48 h. As shown 170 
in Fig. 7A, 30 µmol/L Iso gradually decreased AKT phosphorylation at Ser473 and Thr308. AKT inhibition by Iso 171 
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was accompanied by decreased phosphorylation of GSK3β, a direct target of AKT, at Ser9. Decreased GSK3β 172 
phosphorylation leads to its activation and subsequent activation of MITF transcriptional activity. LY294002, a 173 
direct inhibitor of PI3K/AKT signaling via selective PI3K inhibition, was used as a positive control to confirm the 174 
involvement of PI3K/AKT inhibition for activation of melanogenesis. At a concentration of 10 µmol/L, LY294002 175 
increased B16 melanin content by 4.2-fold in comparison with that of the control group (Fig. 7B).   176 
 177 
Discussion 178 
Flavonoids are attractive natural compounds in health care applications due to their combination of beneficial 179 
bioactivities and low toxicity. Many flavonoids have been reported to control melanogenesis. However, these 180 
different flavonoids exert controversial effects on melanin synthesis in spite of their structural similarity [19-22]. 181 
Recent studies have documented the crucial role of 4'-O-methyl group on the B-ring of flavonoids in the promotion 182 
of melanin synthesis despite the alteration of functionalities of the other position. In fact, 4'-O-methylated flavonoids 183 
highly induce melanogenesis in B16F10 melanoma cells as well as in Sik2+/- mice model [23, 24]. Nevertheless, the 184 
pathways underlying elevation of melanin content by 4'-O-methylated flavonoids are not well understood. In this 185 
study, we explored the effect of Iso, a 4'-O-methylated flavonoid, on melanogenesis in B16 melanoma cells and 186 
used molecular approaches to understand the pathways involved in its effect.  187 
Melanogenesis is a complex mechanism that is related to at least 125 genetic loci [25]. Among the genes involved in 188 
melanogenesis, the tyrosinase family, which consists of Tyr, TRP1, and TRP2, has been recognized as containing the 189 
most critical regulators of melanin biosynthesis. Indeed, tyrosinase family enzymes catalyze the rate-limiting steps 190 
in melanogenesis [26, 27]. As expected, our results showed that Iso, a 4'-O-methylated flavonoid, dose-dependently 191 
induced melanogenesis in B16 melanoma cells. MTT and trypan blue assays showed that Iso decreased the 192 
proliferation rate of B16 melanoma cells at a concentration above 45 µmol/L, but did not affect their viability at all 193 
tested concentrations. In addition, we found that Iso-induced melanogenesis was accompanied by increased 194 
expression of Tyr, TRP1, and TRP2. Moreover, treatment with Iso at 15 and 30 µmol/L increased tyrosinase activity 195 
by 2- and 3.2-fold, respectively. Taken together, our results demonstrate that Iso-induced melanogenesis is mediated 196 
mainly by elevated tyrosinase expression and activity. 197 
MITF is the key transcriptional regulator of melanogenic enzymes [28]. In response to UV light, α-MSH increases 198 
MITF expression by activating cAMP signaling [13]. Activation of protein kinase A (PKA) by cAMP results in 199 
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binding of CRE-binding protein (CREB) to the cAMP regulatory element (CRE) promoter, leading to transcription 200 
of the gene encoding microphthalmia transcription factor (MITF). MITF specifically binds to the M-box and E-box 201 
motifs in the promoter regions of Tyr, TRP1, and TRP2 and up-regulates their expression [29]. Our results showed 202 
an increase in MITF expression upon Iso treatment that reached a maximum level after 12 h. Furthermore, H89, a 203 
specific PKA inhibitor, significantly abolished Iso-stimulated melanogenesis, showing that MITF up-regulation is 204 
mediated by PKA/CREB pathway activation.  205 
Previous research indicated that MAPK signaling pathways (ERK, JNK, and p38) regulate MITF activity [30-32]. 206 
Activation of ERK MAP kinases induces phosphorylation of MITF at Ser73, and, together with recruitment of the 207 
transcriptional coactivator p300, this process leads to ubiquitination and proteasome-mediated degradation of MITF, 208 
finally diminishing tyrosinase synthesis and melanin production [33, 34]. Our western blotting data revealed that Iso 209 
decreased phosphorylation and activation of ERK after 12 h of exposure. Additionally, Iso did not produce 210 
significant differences in phosphorylation of p38 or JNK. The decrease in ERK phosphorylation induced by Iso led 211 
to inhibition of MITF phosphorylation at Ser73 as detected by our experiments after 24 h of exposure, thereby 212 
activating MITF and up-regulating expression of tyrosinase family genes. Furthermore, specific ERK inhibitor 213 
U0126 induced melanin accumulation in B16 melanoma cells. Thus, the results described above suggest that 214 
inhibition of ERK signaling might play an important role in Iso-induced melanogenesis. 215 
Another important signaling pathway involving PI3K/AKT/GSK3β has been suggested to modulate the 216 
transcriptional activity of MITF [15, 16]. Indeed, α-MSH-induced cAMP can inhibit phosphorylation of AKT at 217 
Thr308 and Ser473 through a PI3K-dependent mechanism, thus inhibiting AKT activity [35, 36]. Therefore, 218 
unphosphorylated GSK3β, a molecule downstream of AKT, was activated and phosphorylated MITF at Ser289, 219 
thereby up-regulating tyrosinase family genes, consequently inducing melanogenesis [37]. In this study, we found 220 
that Iso reduced the AKT activity and phosphorylation of AKT at Thr308 and Ser473, which was followed by 221 
inhibition of GSK3β phosphorylation. Among other effects, GSK3β activation leads to activation of MITF and 222 
increased tyrosinase expression. PI3K-specific inhibitor LY294004 was used as a positive control to confirm the 223 
importance of the PI3K/AKT/GSK-3β signaling pathway as an activator of melanogenesis. Exposure to LY294004 224 
increased melanin secretion by 4.2 times in comparison with that of the control group. 225 
 226 
Conclusion 227 
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In this study, we showed that the 4'-O-methylated flavonoid Iso induced melanin synthesis in B16 melanoma cells. 228 
Iso triggered up-regulation of tyrosinase family protein via up-regulation of MITF expression and enhanced MITF 229 
activation. Iso-induced MITF expression and activation was clearly mediated through activation of PKA/CREB 230 
pathway, and inhibition of ERK1/2 and PI3K/AKT signaling pathways. Taken together, the results of this study 231 
demonstrate that Iso is a promising therapeutic compound that could be applied as a treatment for patients with 232 
hypo-pigmentation disorders. 233 
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Figures and legends 330 
Fig. 1 Chemical structure of Isosakuranetin 331 
 332 
Fig. 2 Effect of Iso on melanogenesis and expression of Tyr, TRP1, and TRP2. B16 melanoma cells were cultured 333 
for 48 and 72 h in the presence of several doses of Iso (0–30 µmol/L). Melanin was extracted and measured (A). 334 
Cells were sonicated in a lysis buffer and cellular proteins were subjected to western blotting with antibodies against 335 
Tyr, TRP1, and TRP2 (B). The final DMSO concentration in all samples was 0.1%. Values represent mean ± SD. 336 
Results are representative of 2 different experiments (n = 3). **P < 0.01, ##P < 0.01, versus the control of each 337 
group. 338 
 339 
Fig. 3 Effect of Iso on B16 melanoma cell proliferation and viability. B16 melanoma cells were cultured for 72 h in 340 
the presence of Iso (0–75 µmol/L). Cell proliferation was measured by the MTT assay (A). Cells were trypsinized 341 
and their viability was determined by trypan blue staining (B). The final DMSO concentration in all samples treated 342 
with Iso was 0.1%. Values represent mean ± SD. Results are representative of 3 different experiments (n = 3). **P < 343 
0.01, versus the control group. 344 
 345 
Fig. 4 Effect of Iso on tyrosinase activity in B16 melanoma cells. B16 melanoma cells were cultured in the presence 346 
of Iso (0–30 µmol/L) for 72 h. Cells were harvested and subjected to assessment of tyrosinase activity. Cellular 347 
tyrosinase activity was determined as the ratio of tyrosinase content to total protein content. α-MSH was used in this 348 
experiment as a positive control. The final DMSO concentration in all samples treated with Iso was 0.1%. Values 349 
represent mean ± SD. Results are representative of 3 different experiments (n = 3). **P < 0.01, versus the control 350 
group. 351 
 352 
Fig. 5 Effect of Iso on MITF expression and phosphorylation (A), and PKA inhibitor H89 on Iso-stimulated 353 
melanogeneis (B). B16 melanoma cells were cultured in the presence of Iso (30 µmol/L) for 0, 3, 6, 12, 24, and 48 h. 354 
Cells were harvested in lysis buffer and cellular proteins were subjected to western blotting with antibodies against 355 
MITF and p-MITF Ser73. Band densities were quantified with ImageJ software. Values represent mean ± SD. 356 
Results are representative of 3 different experiments. *P < 0.05, **P < 0.01, versus the control of each group (A). 357 
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B16 melanoma cells were preincubated for 1h in the presence or absence of 5 µmol/L H89, and then Iso (30 358 
µmol/L) was added for an additional 72 h. Melanin was extracted and measured. Values represent mean ± SD. 359 
Results are representative of 2 different experiments (n = 3). **P < 0.01, versus Iso (30 µmol/L) treated group (B). 360 
 361 
Fig. 6 Effect of Iso on ERK1/2, p38, and JNK expression and phosphorylation (A), as well as stimulation of 362 
melanogenesis by ERK1/2 specific inhibitor U0126 in B16 melanoma cells (B). B16 melanoma cells were cultured 363 
in the presence of Iso (30 µmol/L) for 0, 3, 6, 12, 24, and 48 h. Cells were harvested and cellular proteins were 364 
subjected to western blotting with antibodies against ERK1/2, p-ERK1/2, p38, p-p38, JNK, and p-JNK. Band 365 
densities were quantified with ImageJ software. Values represent mean ± SD. Results are representative of 3 366 
independent experiments. *P < 0.05, **P < 0.01, versus the control group (A). B16 cells were cultured in the 367 
presence of ERK specific inhibitor U0126 (10 µmol/L) for 72 h. Cells were harvested and melanin content was 368 
measured. Values represent mean ± SD. Results are representative of 2 different experiments (n = 3). **P < 0.01, 369 
versus the control group (B). 370 
 371 
Fig. 7 Effect of Iso on GSK3β phosphorylation, Akt expression, Akt phosphorylation (A), and stimulation of 372 
melanogenesis by PI3K inhibitor LY294002 in B16 melanoma cells (B). B16 melanoma cells were cultured in the 373 
presence of Iso (30 µmol/L) for 0, 3, 6, 12, 24, and 48 h. Cells were harvested and proteins were subjected to 374 
western blotting with antibodies against p-GSK3β, AKT and p-AKT. Band densities were quantified with ImageJ 375 
software. Values represent mean ± SD. Results are representative of 3 independent experiments. *P < 0.05, **P < 376 
0.01, #P < 0.05, ##P < 0.01, versus the control of each group (A). B16 cells were cultured in the presence of PI3K 377 
inhibitor LY294002 (10 µmol/L) for 72 h. Cells were harvested and melanin content was measured. Values 378 
represent mean ± SD. Results are representative of 2 different experiments (n = 3). **P < 0.01, versus the control 379 
group (B). 380 
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